Healthcare
Live Price
Offline$168.52
+2.64% today
1Y Change
+34.08%
Window
Jun 30, 2025 → Jun 26, 2026
Coverage: 249 bars · Jun 30, 2025 → Jun 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Neurocrine Biosciences, Inc. (NBIX) is a Healthcare stock with a market cap of $13.23B and listed on NASDAQ. The stock last traded around $168.52 and up 34.1% across the available one-year price window (Jun 30, 2025 → Jun 26, 2026). Baseline metrics include revenue growth of +21.4%, EPS growth of +41.5%, a dividend yield of 0.0%. What stands out right now is revenue +21.4%, EPS +41.5%, free cash flow +34.4% with operating margin 21.6% and ROIC 10.8%. Valuation sits in the middle of the pack at P/E 27.4 and price/sales 4.6. Stock Foundry combines NBIX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
NBIX is 16.09 pts ahead over the shared 1Y window.
NBIX had 11.77 pts deeper max drawdown than SPY.
NBIX beat SPY in 2 of 2 calendar years shown and trailed in 0.
NBIX
+34.08%
Normalized return
SPY
+17.99%
S&P 500
Excess Return
+16.09 pts
Relative to SPY
NBIX Max Drawdown
-20.90%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for NBIX and SPY.
| Year | NBIX | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +19.86% | +6.71% | +13.15 pts | NBIX |
| 2025 | +12.14% | +11.19% | +0.95 pts | NBIX |
Unable to load analyst forecasts.
Timed out loading forecasts for NBIX
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.